Investigating how a protein affects cancer growth and signaling pathways
PR55-alpha controlled PP2A in the regulation of the Hippo/YAP pathway
This study is looking at how a protein called PR55-alpha affects the way pancreatic cancer cells grow and behave, with the hope of finding new ways to treat this tough cancer and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10917111 on NIH RePORTER |
What this research studies
This research focuses on pancreatic cancer, one of the deadliest cancers with a very low survival rate. It aims to understand the role of a specific protein, PR55-alpha, in regulating cancer-related signaling pathways, particularly the Hippo/YAP pathway, which is crucial for tumor suppression. By studying how PR55-alpha influences cancer cell behavior, the research seeks to uncover new therapeutic targets that could lead to more effective treatments for pancreatic cancer. Patients may benefit from insights that could lead to novel therapies targeting this pathway.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those with advanced disease.
Not a fit: Patients with early-stage pancreatic cancer or those with other types of cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for pancreatic cancer, improving survival rates and treatment options.
How similar studies have performed: While the specific approach of targeting PR55-alpha in pancreatic cancer is novel, similar studies have shown promise in other cancers by targeting signaling pathways.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Yan, Ying — University of Nebraska Medical Center
- Study coordinator: Yan, Ying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.